Comparing Milestone Pharmaceuticals (NASDAQ:MIST) & Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics (NASDAQ:RANI) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Valuation and Earnings

This table compares Rani Therapeutics and Milestone Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.03 million	154.54	-$30.02 million	($0.79)	-1.66
Milestone Pharmaceuticals	$1.00 million	151.60	-$41.52 million	($0.82)	-2.17

Rani Therapeutics has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rani Therapeutics and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	N/A	-129.00%
Milestone Pharmaceuticals	N/A	-2,374.19%	-85.19%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Milestone Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1	0	3	0	2.50
Milestone Pharmaceuticals	1	2	3	0	2.33

Rani Therapeutics currently has a consensus target price of $8.33, indicating a potential upside of 536.13%. Milestone Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 349.44%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Rani Therapeutics is more favorable than Milestone Pharmaceuticals.

Institutional & Insider Ownership

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 26.5% of Rani Therapeutics shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Rani Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Summary

Rani Therapeutics beats Milestone Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.